Moderna's Growth Projections and New Product Strategies Amid Market Uncertainty

Moderna forecasts sales between $2.5 billion and $3.5 billion for next year, driven by new product launches and significant growth anticipated between 2026 and 2028. Despite a drop in revenue this year, the company is optimistic, banking on new mRNA shots including an RSV vaccine to counter declining COVID vaccine sales.

Sales of Moderna are expected to range between $2.5 billion and $3.5 billion next year, with an anticipated average annual growth rate of 25% in revenue between 2026 and 2028, driven by new product launches. Last month, Moderna projected sales of $3 billion to $3.5 billion for the current year, its lowest since launching its COVID-19 vaccine in 2020.

Analysts predict revenues of $3.27 billion and $3.74 billion for 2024 and 2025 respectively, according to LSEG data. Despite these optimistic projections, shares of Moderna were down 7% at $73.94 in premarket trading, reflecting market uncertainties.

Moderna anticipates a return to sales growth by 2025, with CFO James Mock citing uncertainties in the COVID and RSV markets. Moderna plans to submit applications to the FDA for expanded use and combination vaccines, betting on new mRNA shots like the RSV vaccine mRESVIA to offset declining COVID vaccine revenue. The company's standalone flu vaccine also met immune-response targets in recent studies, with further efficacy studies planned for this year.

(With inputs from agencies.)